RFA-AI-23-059. Development of Candidate Radiation/Nuclear Medical Countermeasures (MCMs) (U01 Clinical Trial Not Allowed)

Leading Research to Understand, Treat, and Prevent Infectious, Immunologic, and Allergic Diseases          Visit us on the Web   RFA-AI-23-059. Development of Candidate Radiation/Nuclear Medical Countermeasures (MCMs) (U01 Clinical Trial Not Allowed) Optional letter of intent due - December 26, 2023  Receipt date for full applications - January 26, 2024  Review - July 2024  Start date - December 2024    The purpose of this Notice of Funding Opportunity (NOFO) is to support early to mid-stage research focused on development of candidate medical countermeasures (MCMs) with post-radiation exposure administration data demonstrating efficacy to mitigate and/or treat radiation injuries. Product development should focus on mitigating acute radiation syndromes and/or the delayed effects of acute radiation exposure. Additionally, elucidation of mechanisms of action of MCMs necessary to meet product licensure requirements is of interest.    Please contact:  Carmen Rios, PhD  Program Officer   carmen.rios@nih.gov  Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107